4. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:343-346

5. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271-280.
6. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 274:33238–33243.
7. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277:14838–14843.
8. Hamming I, Timens W, Bulthuis MLC, et al. Tissue distribution of ACE2 protein, the functional receptor of SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203:631-637
9. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibitor and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-2610.
10. Campbell DJ, Zeitz CJ, Esler MD et al. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE 2) in angiotensin peptide metabolism in human coronary circulation. J Hypertens 2004; 22:1971-1976.
11. Luque M, Martin P, Martell N, et al. Effects of captopril relate to increased levels of prostacyclin and angiotensin (1-7) in essential hypertension. J Hypertens 1996; 14:799-805.
12. Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep 2014; 4:7027.
13. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63:364-374.
14. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep 2016; 6:19840.
15. Kuba K, Imayi Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS-coronavirus-induced lung injury. Nat Med 2005; 11:875-879.
16. Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerated maladaptive left ventricular remodelling in response to myocardial infarction. Circ Heart Fail 2009; 2:446-455.
17. Zeng Z, Sha T, Zhang Y et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20054825
18. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. medRxiv 2020.03.20.20039586; doi: https//doi.org/10.1101/2020.03.20.20039586.
19. Yang G, Tan Z, Lou Z et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-Patients With Hypertension. . medRxiv preprint doi: https://doi.org/10.1101/2020.03.31.20038935
20. Bean D, Kraljevic Z, Searle T, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-COVID-19 infection in a multi-sile UK acute Hospital Trust. medRxiv 2020.04.07.20056788; doi: https//doi.org/10.1101/2020.04.07.20056788
21. Zhang P, Zhu L, Cai J et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. DOI: 10.1161/CIRCRESAHA.120.317134
22. Li J, Wang X, Chen J et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. (2020) doi:10.1001/jamacardio.2020.1624
23. Montecucco F, Pende A, Mach F. The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies. Mediators of Inflammation 2009, doi:10.1155/2009/752406
24. Dandona P, Dhindsa S, Ghanim H. et al.  Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens  21 20–27 (2007). https://doi.org/10.1038/sj.jhh.1002101
25. European Societies of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. March 13, 2020. Available at: https://www.escardio. org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on hyper tension-on-ace-inhibitors-and-ang.
26. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. March 17, 2020. Available at: https://www.acc. org/latest-in-cardiology/ artic les/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
27. A statement from the International Society of Hypertension on COVID-19. March 16,2020. Available at: https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/
28. Sekizawa K, Matsui T, Nakagawa T. ACE inhibitors and Pneumonia. Lancet 1998, 352: 1069